SmallCaps
ASX:TRIHealth Care Equipment & ServicesHealth Care Technology

TrivarX Ltd

$0.022
Day Range
$0.021 – $0.022
52 Week Range
$0.007 – $0.035
Volume
0.00
Avg Volume (10D)
566.11K
Market Cap
$25.38M

Price Chart

OHLC · volume · moving averages

$0.022+$0.002 (+10.00%)over 6M
Hi$0.032Lo$0.015
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.022
Previous Close
$0.022
Day High
$0.022
Day Low
$0.021
52 Week High
$0.035
52 Week Low
$0.007

Valuation

Fundamental multiples

Market Cap
25.38M
Shares Outstanding
1.15B
Price to Book
1.03

Trading Activity

Volume & order book

Volume
0.00
Value Traded
0.00
Bid
$0.022 × 1,000,000
Ask
$0.023 × 599,040

Performance

Returns across timeframes

1 Day
-4.55%
5 Day
-8.70%
13 Week
23.53%
52 Week
133.33%
YTD
10.53%

Technical Indicators

Momentum & moving averages

RSI (14)
44.02
50-Day SMA
$0.024
200-Day SMA
$0.020

— From the desk

Latest News

TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours
Biotechnology

TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours

TrivarX (ASX: TRI) has announced plans to acquire novel Stabl-Im metastatic brain technology and associated stable isotope cancer diagnostic intellectual property from Australian company Nucleics. Stabl-Im represents a potential breakthrough in the safe and non-invasive detection of brain cancers and metastases using standard magnetic resonance imaging (MRI) equipment to visualise and monitor tumour growth without the […]

TrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes
Biotechnology

TrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes

An extensive research and development (R&D) program by mental health technology company TrivarX (ASX: TRI) has advanced the company’s proprietary artificial intelligence-backed algorithm MEB-001 for the screening of current major depressive episode (cMDE). The algorithm can accurately conduct sleep staging and screen for cMDE in subjects through a single-channel electrocardiogram, using heart rate and heart […]

TrivarX completes Phase 2 MEB-001 algorithm sleep study for depressive episodes
Biotechnology

TrivarX completes Phase 2 MEB-001 algorithm sleep study for depressive episodes

Medical health technology company TrivarX (ASX: TRI) has completed a Phase 2 sleep signal analysis for current major depressive episode (SAMDE) study utilising its proprietary artificial intelligence-backed algorithm MEB-001. The study aimed to validate MEB-001 in the screening and diagnosis of current major depressive episodes in 400 participants enrolled at 15 sleep centres across the […]